Kiora Pharmaceuticals Stock Buy Hold or Sell Recommendation
| KPRX Stock | USD 3.25 0.10 2.99% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Kiora Pharmaceuticals is 'Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Kiora Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Kiora Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Kiora Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide. In addition, we conduct extensive research on individual companies such as Kiora and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Kiora Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Kiora |
Execute Kiora Pharmaceuticals Buy or Sell Advice
The Kiora recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Kiora Pharmaceuticals. Macroaxis does not own or have any residual interests in Kiora Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Kiora Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Kiora Pharmaceuticals Trading Alerts and Improvement Suggestions
| Kiora Pharmaceuticals generated a negative expected return over the last 90 days | |
| Kiora Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (12.51 M) with loss before overhead, payroll, taxes, and interest of (5.14 M). | |
| Kiora Pharmaceuticals currently holds about 2.43 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64. | |
| Kiora Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema |
Kiora Pharmaceuticals Returns Distribution Density
The distribution of Kiora Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Kiora Pharmaceuticals' future price movements. The chart of the probability distribution of Kiora Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Kiora Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Kiora Pharmaceuticals returns is essential to provide solid investment advice for Kiora Pharmaceuticals.
| Mean Return | 0.05 | Value At Risk | -5.87 | Potential Upside | 7.44 | Standard Deviation | 4.09 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Kiora Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Kiora Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Kiora Pharmaceuticals, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Kiora Pharmaceuticals back and forth among themselves.
| Shares | Goss Wealth Management Llc | 2024-12-31 | 22.0 | Bank Of America Corp | 2024-12-31 | 20.0 | U.s. Bancorp | 2024-12-31 | 8.0 | Advisor Group Holdings, Inc. | 2024-12-31 | 3.0 | Ubs Group Ag | 2024-12-31 | 2.0 | Activest Wealth Management | 2024-12-31 | 2.0 | Sbi Securities Co Ltd | 2024-12-31 | 1.0 | Susquehanna International Group, Llp | 2024-12-31 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 0.0 | Aigh Capital Management, Llc | 2024-12-31 | 255.6 K | Rosalind Advisors, Inc. | 2024-12-31 | 250.6 K |
Kiora Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (2.6M) | 6.7M | (1.9M) | (3.6M) | (4.1M) | (3.9M) | |
| Free Cash Flow | (7.5M) | (11.0M) | (10.4M) | (9.6M) | (8.6M) | (9.0M) | |
| Depreciation | 33.4K | 45.3K | 41.6K | 62.4K | 71.8K | 43.7K | |
| Other Non Cash Items | 326.7K | 6.0M | 2.1M | 3.9M | 4.5M | 4.7M | |
| Capital Expenditures | 20.1K | 133.8K | 63.9K | 1.0 | 1.15 | 1.09 | |
| Net Income | (8.1M) | (16.4M) | (13.6M) | (12.5M) | (11.3M) | (11.8M) | |
| End Period Cash Flow | 1.2M | 7.9M | 6.0M | 2.5M | 2.8M | 4.8M | |
| Net Borrowings | (9.8K) | (4.7K) | 278.2K | (212.3K) | (191.1K) | (181.5K) | |
| Change To Netincome | 961.3K | 1.4M | 895.8K | 6.3M | 7.3M | 7.6M |
Kiora Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Kiora Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Kiora Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Kiora stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.06 | |
β | Beta against Dow Jones | 0.53 | |
σ | Overall volatility | 4.01 | |
Ir | Information ratio | 0.02 |
Kiora Pharmaceuticals Volatility Alert
Kiora Pharmaceuticals shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Kiora Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Kiora Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Kiora Pharmaceuticals Fundamentals Vs Peers
Comparing Kiora Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Kiora Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Kiora Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Kiora Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Kiora Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Kiora Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Kiora Pharmaceuticals to competition |
| Fundamentals | Kiora Pharmaceuticals | Peer Average |
| Return On Equity | 0.14 | -0.31 |
| Return On Asset | 0.13 | -0.14 |
| Profit Margin | 0.20 % | (1.27) % |
| Operating Margin | (121.23) % | (5.51) % |
| Current Valuation | (18.9 M) | 16.62 B |
| Shares Outstanding | 2.97 M | 571.82 M |
| Shares Owned By Insiders | 2.30 % | 10.09 % |
| Shares Owned By Institutions | 48.34 % | 39.21 % |
| Number Of Shares Shorted | 72.08 K | 4.71 M |
| Price To Book | 0.34 X | 9.51 X |
| Price To Sales | 0.61 X | 11.42 X |
| Gross Profit | (5.14 M) | 27.38 B |
| EBITDA | (12.35 M) | 3.9 B |
| Net Income | (12.51 M) | 570.98 M |
| Cash And Equivalents | 2.43 M | 2.7 B |
| Cash Per Share | 2.64 X | 5.01 X |
| Total Debt | 106.89 K | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 1.53 X | 2.16 X |
| Book Value Per Share | 7.14 X | 1.93 K |
| Cash Flow From Operations | (9.56 M) | 971.22 M |
| Short Ratio | 0.27 X | 4.00 X |
| Earnings Per Share | 16.53 X | 3.12 X |
| Target Price | 30.33 | |
| Number Of Employees | 12 | 18.84 K |
| Beta | -0.29 | -0.15 |
| Market Capitalization | 10.75 M | 19.03 B |
| Total Asset | 13.71 M | 29.47 B |
| Retained Earnings | (146.98 M) | 9.33 B |
| Working Capital | 3.1 M | 1.48 B |
| Net Asset | 13.71 M |
Note: Acquisition by Shapiro Aron of 3000 shares of Kiora Pharmaceuticals at 3.6 subject to Rule 16b-3 [view details]
Kiora Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Kiora . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 515.85 | |||
| Daily Balance Of Power | (0.77) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 3.29 | |||
| Day Typical Price | 3.27 | |||
| Price Action Indicator | (0.09) | |||
| Period Momentum Indicator | (0.10) |
About Kiora Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Kiora Pharmaceuticals? Buying financial instruments such as Kiora Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Kiora Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run RUB Crypto Assets Thematic Idea Now
RUB Crypto Assets
An experimental p2p digital currency that is accepted by many vendors in Russian Ruble. The RUB Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize RUB Crypto Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.